Operating income before deduction of amortization: maravai.com (MRVI)

The stable cash flow of Maravai LifeSciences (MRVI) confirms the business's resilience, as visualized by the EBITDA financial metric through a comparison of current earnings with previous peaks. The 18.27 indicator determines the status of the operational efficiency parameter. Growth is based on partnerships with mRNA drug developers, although reductions in client R&D budgets and the decline in pandemic-driven demand create certain risks for margins.

Profit before payment of interest, taxes and amortization: Maravai LifeSciences (MRVI) for 11/23/2025 - 11/15/2026

Maravai LifeSciences Holdings (MRVI) - metric breakdowns and financial figures

- market value and analyst target forecast:

Market Price maravai.com|MRVI - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Maravai LifeSciences Holdings, Inc.|MRVI - Enterprise Value

- balance sheet equity data:

Net Assets per Share Maravai LifeSciences|MRVI - Company Book Value|Market Capitalization to Book Value maravai.com|MRVI - Aggregate Company Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

MRVI - Net Profit|Projected Future Earnings Maravai LifeSciences|MRVI - P/E Multiple|Market Cap to Projected Earnings Maravai LifeSciences Corp|MRVI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Maravai LifeSciences Holdings|MRVI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Maravai LifeSciences|MRVI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months maravai.com|MRVI - Earnings growth in current year|Net earnings per share change forecast for next year Maravai LifeSciences

- sales and revenue data:

MRVI - Revenue and Sales Volume|Company Expected Sales Volume maravai.com|MRVI - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Maravai LifeSciences Holdings, Inc.

Analysis of all company metrics:Maravai LifeSciences

Mass-produced product of Maravai LifeSciences Holdings, Inc.

The investment attractiveness of Maravai LifeSciences (MRVI) depends on the efficiency of operating expense management. This indicator captures the average daily cash flow from operating activities before taxes and interest. By analyzing the company's total operating profit, an investor assesses the business's actual ability to act as a cash generator. The stability of this curve confirms the optimization of outsourcing costs for production and logistics. Such metrics determine fundamental stability and the long-term cost of capital.

Who Maravai LifeSciences competes with

Operating income before deduction of amortization Agilent Technologies (A)|Quest Diagnostics Inc. - Operating profit EBITDA|Operating income before deduction of amortization Illumina ILMN|EXAS: Operating profit EBITDA|RVTY - Operating income before deduction of amortization|BIO (Bio-Rad Laboratories) - Operating profit EBITDA|Anbio Biotechnology (NNNN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Nordion (SHC)|QuidelOrtho Corp (QDEL) - Operating profit before depreciation charges|Profit before payment of interest, taxes and amortization OPKO Health Inc OPK|Operating profit EBITDA CareDx, Inc CDNA|FLGT - Profit before payment of interest, taxes and amortization|LAB (Standard BioTools Inc.) - Operating profit before amortization|CTKB: Operating profit EBITDA|OSUR - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Exagen|Profit before interest, taxes and amortization MDxHealth Inc. MDXH|Operating profit before deduction of amortization LUCD (Lucid Diagnostics Inc.)|Operating income before deduction of amortization Prenetics|Insight Molecular Diagnostics Inc - Operating profit before deduction of amortization|trinitybiotech.com (TRIB) - Profit before interest, taxes and amortization|prophaselabs.com - Operating profit EBITDA|AIMD (Ainos Corp) - Operating profit before amortization|Co-Diagnostics Inc (CODX) - Profit before payment of interest, taxes and amortization|HSCS - Operating income before deduction of amortization|Operating profit before deduction of amortization BMRA|Operating profit EBITDA Cardio Diagnostics|Operating profit EBITDA ONCO|Operating profit EBITDA Virax Biolabs Group Ltd (VRAX)|Operating profit EBITDA BJDX (Bluejay Diagnostics Corp)|Operating income before deduction of amortization Aspira Women's Health Inc. (AWH)|Accelerate Diagnostics Inc. - Operating profit EBITDA|CNTG: Profit before payment of interest, taxes and amortization|Enzo Biochem, Inc. (ENZ) - Profit before payment of interest, taxes and amortization|fresh2.co (FRES) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Genetic Technologies|Profit before interest, taxes and amortization 23andMe ME|Operating profit EBITDA PMD